Literature DB >> 16616846

AlOH3-adjuvanted vaccine-induced macrophagic myofasciitis in rats is influenced by the genetic background.

François-Jérôme Authier1, Stéphane Sauvat, Christo Christov, Patrick Chariot, Grant Raisbeck, Marie-Françoise Poron, Françoise Yiou, Romain Gherardi.   

Abstract

Macrophagic myofasciitis (MMF) is a specific histopathologic lesion involved in the persistence for years of aluminum hydroxide [Al(OH)(3)] at the site of previous intramuscular (i.m.) injection. In order to study mechanisms involved persistence of MMF lesions, we set up an experimental model of MMF-lesion in Sprague-Dawley and Lewis rat, by i.m. injections of 10 microL of an Al(OH)(3)-adjuvanted vaccine. An evaluation carried out over a 12-month period disclosed significant shrinkage of MMF lesions with time. A radioisotopic study did not show significant aluminium uptake by Al(OH)(3)-loaded macrophages. A morphometric approach showed that Lewis rats with Th1-biased immunity had significantly smaller lesions than Sprague-Dawley rats with balanced Th1/Th2 immunity. Concluding, our results indicate that genetic determinatives of cytotoxic T-cell responses could interfere with the clearance process and condition the persistence of vaccine-induced MMF-lesions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16616846     DOI: 10.1016/j.nmd.2006.02.004

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  11 in total

Review 1.  Macrophagic myofaciitis a vaccine (alum) autoimmune-related disease.

Authors:  Eitan Israeli; Nancy Agmon-Levin; Miri Blank; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2011-10       Impact factor: 8.667

2.  Macrophagic myofasciitis: characterization and pathophysiology.

Authors:  R K Gherardi; F J Authier
Journal:  Lupus       Date:  2012-02       Impact factor: 2.911

3.  Selective elevation of circulating CCL2/MCP1 levels in patients with longstanding post-vaccinal macrophagic myofasciitis and ASIA.

Authors:  Josette Cadusseau; Nilusha Ragunathan-Thangarajah; Mathieu Surenaud; Sophie Hue; Francois-Jérôme Authier; Romain K Gherardi
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530

4.  The mechanisms of action of vaccines containing aluminum adjuvants: an in vitro vs in vivo paradigm.

Authors:  Tirth Raj Ghimire
Journal:  Springerplus       Date:  2015-04-16

Review 5.  Clinical features in patients with long-lasting macrophagic myofasciitis.

Authors:  Muriel Rigolet; Jessie Aouizerate; Maryline Couette; Nilusha Ragunathan-Thangarajah; Mehdi Aoun-Sebaiti; Romain Kroum Gherardi; Josette Cadusseau; François Jérôme Authier
Journal:  Front Neurol       Date:  2014-11-28       Impact factor: 4.003

Review 6.  Biopersistence and brain translocation of aluminum adjuvants of vaccines.

Authors:  Romain Kroum Gherardi; Housam Eidi; Guillemette Crépeaux; François Jerome Authier; Josette Cadusseau
Journal:  Front Neurol       Date:  2015-02-05       Impact factor: 4.003

Review 7.  Vaccines, adjuvants and autoimmunity.

Authors:  Luísa Eça Guimarães; Britain Baker; Carlo Perricone; Yehuda Shoenfeld
Journal:  Pharmacol Res       Date:  2015-08-12       Impact factor: 7.658

8.  Cytokines profile in neonatal and adult wild-type mice post-injection of U. S. pediatric vaccination schedule.

Authors:  S C Bairwa; C A Shaw; M Kuo; J Yoo; L Tomljenovic; H Eidi
Journal:  Brain Behav Immun Health       Date:  2021-05-17

9.  Slow CCL2-dependent translocation of biopersistent particles from muscle to brain.

Authors:  Zakir Khan; Christophe Combadière; François-Jérôme Authier; Valérie Itier; François Lux; Christopher Exley; Meriem Mahrouf-Yorgov; Xavier Decrouy; Philippe Moretto; Olivier Tillement; Romain K Gherardi; Josette Cadusseau
Journal:  BMC Med       Date:  2013-04-04       Impact factor: 8.775

10.  Macrophagic myofasciitis and subcutaneous pseudolymphoma caused by aluminium adjuvants.

Authors:  Hyunhee Kim; Ka Young Lim; Jeongwan Kang; Jin Woo Park; Sung-Hye Park
Journal:  Sci Rep       Date:  2020-07-16       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.